COMPLETE REMISSION IN REFRACTORY ANAPLASTIC ADULT WILMS-TUMOR TREATED WITH CISPLATIN AND ETOPOSIDE

被引:0
|
作者
SPARANO, JA
BECKWITH, JB
MITSUDO, S
WIERNIK, PH
机构
[1] MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT PATHOL,BRONX,NY 10467
[2] CHILDRENS HOSP,DEPT PATHOL,DENVER,CO 80218
关键词
D O I
10.1002/1097-0142(19910215)67:4<956::AID-CNCR2820670417>3.0.CO;2-H
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A 61-year-old woman underwent a left radical nephrectomy for Stage II anaplastic Wilms' tumor. She received no adjuvant therapy. One year later computerized tomography (CT) of the abdomen revealed a mass in the left renal fossa and retroperitoneal adenopathy. A CT-guided needle biopsy was nondiagnostic. The patient had progressive disease after treatment with dactinomycin, doxorubicin, and vincristine, but achieved a complete response after treatment with cisplatin and etoposide. The therapy of Wilms' tumor in adults is discussed.
引用
收藏
页码:956 / 959
页数:4
相关论文
共 50 条
  • [41] TREATMENT OF CHILDREN WITH STAGE-II TO STAGE-IV ANAPLASTIC WILMS-TUMOR - A REPORT FROM THE NATIONAL-WILMS-TUMOR-STUDY-GROUP
    GREEN, DM
    BECKWITH, JB
    BRESLOW, NE
    FARIA, P
    MOKSNESS, J
    FINKLESTEIN, JZ
    GRUNDY, P
    THOMAS, PRM
    KIM, T
    SHOCHAT, S
    HAASE, G
    RITCHEY, M
    KELALIS, P
    DANGIO, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2126 - 2131
  • [42] P53 MUTATIONS ASSOCIATED WITH ANAPLASTIC WILMS-TUMOR, A HISTOLOGICAL SUBTYPE WITH POOR-PROGNOSIS
    BARDEESY, N
    FALKOFF, D
    PETRUZZI, MJ
    ZABEL, B
    NOWAK, N
    SHOWS, T
    PELLETIER, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 198 - 198
  • [43] PRIMARY GLIAL TUMOR PATIENTS TREATED BY COMBINING CISPLATIN AND ETOPOSIDE
    BOIARDI, A
    SILVANI, A
    MILANESI, I
    BOTTURI, M
    BROGGI, G
    JOURNAL OF NEURO-ONCOLOGY, 1991, 11 (02) : 165 - 170
  • [44] COMPLETE RESPONSE OF THYMIC SEMINOMA TREATED WITH CISPLATIN-ETOPOSIDE DOUBLET
    Reddy, D.
    Kassaby, S.
    Chakraborty, K.
    Jaishankar, D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 480 - 481
  • [45] Complete remission of a "novel agent"-refractory secondary plasma cell leukemia (sPCL) after polychemotherapy with dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE)
    Desuki, A.
    Jacobi, B.
    Euler, P.
    Wagner, E. -M
    Theobald, M.
    Woelfel, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 289 - 289
  • [46] CHONDROSARCOMA OF BONE AS 2ND TUMOR AFTER DIFFUSE ANAPLASTIC WILMS-TUMOR - DIAGNOSIS BY FINE-NEEDLE ASPIRATION CYTOLOGY
    DRUT, R
    POLLONO, D
    DIAGNOSTIC CYTOPATHOLOGY, 1993, 9 (02) : 205 - 208
  • [47] Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue
    vanBesien, K
    Verschraegen, C
    Mehra, R
    Giralt, S
    Kudelka, AP
    Edwards, CL
    Piamsonboom, S
    Termrungruanglert, W
    Champlin, R
    Kavanagh, JJ
    GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 366 - 369
  • [48] EXPRESSION OF THE WILMS-TUMOR (WT1) SUPPRESSOR GENE IN THE ADULT-MOUSE KIDNEY
    LINDER, CY
    STRIKER, LJ
    HE, CJ
    LIU, ZH
    PETEN, EP
    STRIKER, GE
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 697 - 697
  • [49] EXPRESSION OF A POSSIBLE CONSTITUTIONAL HOT-SPOT IN SPERM CHROMOSOMES OF A PATIENT TREATED FOR WILMS-TUMOR
    GENESCA, A
    MIRO, R
    CABALLIN, MR
    BENET, J
    NAVARRO, J
    TEMPLADO, C
    BONFILL, X
    EGOZCUE, J
    CANCER GENETICS AND CYTOGENETICS, 1987, 29 (01) : 91 - 96
  • [50] Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
    Maeda, T.
    Hosen, N.
    Fukushima, K.
    Tsuboi, A.
    Morimoto, S.
    Matsui, T.
    Sata, H.
    Fujita, J.
    Hasegawa, K.
    Nishida, S.
    Nakata, J.
    Nakae, Y.
    Takashima, S.
    Nakajima, H.
    Fujiki, F.
    Tatsumi, N.
    Kondo, T.
    Hino, M.
    Oji, Y.
    Oka, Y.
    Kanakura, Y.
    Kumanogoh, A.
    Sugiyama, H.
    BLOOD CANCER JOURNAL, 2013, 3 : e130 - e130